-

08:37:04 PM

LIVE Real Time MDT Stock Market News

MDT - Medtronic Plc

04/21/21 8:00 AM

NYSE : MDT

Medtronic Receives U.S. FDA Approval for Pipeline(TM) Flex Embolization Device with Shield Technology(TM)

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug

RHEA-AI

neutral

04/20/21 12:30 PM

NYSE : MDT

IN.PACT(TM) AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the safety and effectiveness results through 24 months for the IN.PACT

RHEA-AI

neutral

04/14/21 9:00 AM

NYSE : MDT

Medtronic Announces European Launch of World's First Infusion Set with Wear up to Seven Days to Help Reduce Burden for People with Diabetes

Medtronic plc (NYSE: MDT), the global leader in medical technology, today introduced in select European countries the Medtronic Extended infusion set -- the first and only infusion set that can be worn for up to 7 days. An infusion set is tubing that delivers

RHEA-AI

positive

04/12/21 7:00 AM

NYSE : MDT

U.S. FDA Grants De Novo Clearance for First and Only Artificial Intelligence System for Colonoscopy; Medtronic Launches GI Genius(TM) Intelligent Endoscopy Module

- The GI Genius (TM) Module Assists Physicians in Detecting Pre-Cancerous Growths; Potentially Addressing 19 Million Colonoscopies Annually- Transformative AI Colorectal Cancer Prevention Platform Expands Medtronic Capabilities in Medical Technology Data Analytics and InsightsDUBLIN, April 12, 2021

RHEA-AI

neutral

04/07/21 9:10 AM

NYSE : MDT

Medtronic Announces Ongoing Initiatives to Address Health Equity for People of Color Living with Diabetes

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its ongoing commitment to health equity for people of color living with diabetes. The company committed investments in partnerships with the American Diabetes Association(R) (

RHEA-AI

neutral

04/07/21 9:00 AM

NYSE : MDT

The Medtronic Foundation and Children's Heartlink Focus New Partnership on Health Equity for 10,000 Children and 10,000 Health Workers in Underserved Countries

The $2.5 Million USD Multi-Year Partnership Builds Capacity to Provide Pediatric Heart Surgery to 10,000 Children and Trains 10,000 Health Workers in Brazil, India, and China. The Partnership Strengthens Hospital Capacity, Reduces Health Disparities in Access to Care, and Engages Medtronic

RHEA-AI

very positive

03/26/21 1:34 PM

NYSE : MDT

Medtronic Receives FDA Approval for "Breakthrough" Transcatheter Pulmonary Valve Replacement for Patients with Congenital Heart Disease

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for its Harmony(TM) Transcatheter Pulmonary Valve (TPV), the first minimally invasive therapy created to treat

RHEA-AI

positive

03/22/21 8:30 AM

NYSE : MDT

Medtronic Receives CE Mark Approval for SenSight(TM) Directional Lead System for DBS Therapy

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the CE (Conformite Europeenne) Mark for the SenSight(TM) directional lead

RHEA-AI

very positive

03/17/21 9:00 AM

NYSE : MDT

Medtronic Receives Approval for U.S. Labeling of the Intellis(TM) Platform Showing Superior Back Pain Relief When Using DTM(TM) Spinal Cord Stimulation

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) has approved revised commercial labeling for the Intellis(TM) Platform with Differential Target Multiplexed (DTM(TM)) programming for the

RHEA-AI

very positive

03/08/21 6:45 AM

NYSE : MDT

Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2021

The board of directors of Medtronic plc (NYSE: MDT) on Friday, March 5, 2021, approved the fiscal year 2021 fourth quarter cash dividend of $0.58 per ordinary share, representing a 7.4 percent increase over the prior year. This quarterly declaration is

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next